CLINICAL TRIALS PROFILE FOR TRIDIL

All Clinical Trials for TRIDIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03158532 ↗	Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin	Recruiting	Instituto de Cardiologia de Santa Catarina	Phase 3	2017-07-06	The radial approach for a coronary angiography has became popular in several centers because of its simplicity and fewer complications. The radial artery occlusion (RAO) is the main inconvenient and impose a limitation of future use of the radial artery as an access site for catheterization in the future. Several strategies have been used to decrease the incidence of RAO (heparin, patent hemostasis, etc). Nitrates in intra-arterial have been widely studied in prevention of this spasm. Current data show that nitroglycerin intra-arterial at the end of the procedure reduce the incidence of RAO. The hypothesis that use of nitroglycerin at the start of catheterization would have the same effect was not tested.
NCT03059316 ↗	Effect of Hypotensive Anesthesia on the Perfusion Index	Completed	Cairo University	Early Phase 1	2016-06-10	Controlled hypotension has been used as a mean of reducing intraoperative blood loss and better visualization of the surgical field in nasal surgeries. Perfusion index has been considered a useful tool for monitoring changes in peripheral perfusion using Masimo set and serum lactate for central perfusion. Many medications were used to induce hypotension. In this study we will compare the effects of tridil and labetalol on the perfusion.
NCT02343276 ↗	Randomized Clinical Trial Comparing Transradial Catheterization With or Without Spasmolytic Drugs	Completed	Instituto de Cardiologia de Santa Catarina	Phase 3	2015-02-01	Single-center study, randomized, double-blind, placebo controlled, with patients undergoing diagnostic or therapeutic catheterization via the transradial approach. Patients will be randomized into two groups: one group will receive the vasodilator nitroglycerin during the procedure (intervention group), and a second group will receive saline 0.9% in the same volume and time during the procedure (control group). Will be evaluated: incidence of spasms of the radial artery, ability to perform the procedure without the need to change the access site, pain presented by the patient, time and total radiation of the procedure.

Clinical Trial Conditions for TRIDIL

Condition Name

Condition Name for TRIDIL
Intervention	Trials
Cardiac Catheterisation	1
Controlled Hypotension for Nasal Surgeries	1
Injury of Radial Artery	1

Condition MeSH

Condition MeSH for TRIDIL
Intervention	Trials
Hypotension	1

Clinical Trial Locations for TRIDIL

Trials by Country

+

−

Trials by Country for TRIDIL
Location	Trials
Brazil	6

Clinical Trial Progress for TRIDIL

Clinical Trial Phase

Clinical Trial Phase for TRIDIL
Clinical Trial Phase	Trials
Phase 3	2
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for TRIDIL
Clinical Trial Phase	Trials
Completed	2
Recruiting	1

Clinical Trial Sponsors for TRIDIL

Sponsor Name

Sponsor Name for TRIDIL
Sponsor	Trials
Instituto de Cardiologia de Santa Catarina	2
Cairo University	1

Sponsor Type

Sponsor Type for TRIDIL
Sponsor	Trials
Other	3

Clinical Trials, Market Analysis, and Projections for Medical Nitroglycerin Sprays (Including TRIDIL)

Introduction to Medical Nitroglycerin Sprays

Medical nitroglycerin sprays are a class of medications used primarily for the immediate relief of angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart. These sprays contain nitroglycerin, a vasodilator that helps to relax and widen blood vessels, improving blood flow and reducing the workload on the heart.

Clinical Trials Overview

While the specific term "TRIDIL" is not mentioned in the sources, we can discuss the broader context of clinical trials for medical nitroglycerin sprays and related medications.

Current Clinical Trials Landscape

Clinical trials for medications like nitroglycerin sprays are crucial for establishing safety, efficacy, and optimal dosing. These trials often involve randomized, double-blind, placebo-controlled studies to ensure robust data. For example, the clinical trials for other cardiovascular medications, such as obicetrapib, have shown significant reductions in LDL-C and adverse cardiovascular events, highlighting the importance of rigorous clinical testing[4].

Challenges and Opportunities

Clinical trials face several challenges, including stringent regulatory procedures, data security and privacy concerns, and patient recruitment and retention issues. However, advancements in technology, such as the integration of big data analytics, AI, and IoT, can streamline processes and enhance data accuracy[3].

Market Analysis for Medical Nitroglycerin Sprays

Global Market Size and Growth

The global medical nitroglycerin sprays market is projected to experience significant growth over the next decade. According to Zion Market Research, the market was valued at USD 815.45 million in 2023 and is expected to reach USD 1685.24 million by 2032, with a CAGR of 8.4% during the forecast period[5].

Regional Market Analysis

The market is segmented by region, with North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa being key areas. Each region has its own market dynamics and growth prospects. For instance, the North American market is expected to remain a significant contributor due to high healthcare spending and advanced healthcare infrastructure[5].

Distribution Channels

Conventional retail pharmacies currently dominate the market, accounting for approximately half of the overall revenue share. However, online pharmacies are gaining momentum, driven by increased digital literacy and the impact of the pandemic on purchasing habits[5].

Key Players and Market Competition

The medical nitroglycerin sprays market includes several key players such as Perrigo Company Plc., Troikaa Pharmaceuticals Ltd., Dalmia Bros. Pvt. Ltd., and others. These companies compete based on product efficacy, pricing, distribution networks, and innovation in delivery systems[2][5].

Market Drivers and Restraints

Drivers

• Increasing Demand for Immediate Relief: The growing need for quick and effective relief from angina pectoris drives the demand for medical nitroglycerin sprays.
• Advancements in Delivery Systems: Innovations in spray formulations and delivery mechanisms enhance patient compliance and efficacy.
• Expanding Distribution Channels: The rise of online pharmacies and strong distribution networks support market growth[5].

Restraints

• Prolonged Migraines: Frequent use of nitroglycerin sprays can lead to prolonged migraines, which may deter some patients.
• Regulatory Challenges: Stringent regulatory requirements can slow down the approval process for new products or formulations[2].

Future Projections and Trends

Technological Advancements

The integration of digital technologies in healthcare, such as telemedicine and remote monitoring, is expected to enhance the accessibility and effectiveness of medical nitroglycerin sprays.

Patient-Centric Approaches

There is a growing trend towards patient-centric trials and treatments, which could improve patient recruitment, retention, and overall satisfaction with these medications[3].

Real-World Evidence (RWE) Studies

The use of real-world data in clinical trials can provide valuable insights into the long-term efficacy and safety of medical nitroglycerin sprays, further solidifying their market position[3].

Key Takeaways

• Growing Market: The global medical nitroglycerin sprays market is expected to grow significantly, driven by increasing demand and advancements in delivery systems.
• Regional Variations: Market growth varies by region, with North America and Europe being key contributors.
• Distribution Channels: Conventional retail pharmacies dominate, but online pharmacies are gaining traction.
• Technological Integration: Digital technologies and real-world evidence studies are expected to enhance market growth and patient outcomes.

Frequently Asked Questions (FAQs)

Q1: What is the primary use of medical nitroglycerin sprays? Medical nitroglycerin sprays are primarily used for the immediate relief of angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart.

Q2: What is the projected growth rate of the medical nitroglycerin sprays market? The global medical nitroglycerin sprays market is projected to grow at a CAGR of 8.4% from 2023 to 2032[5].

Q3: Which regions are key contributors to the medical nitroglycerin sprays market? North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the key regions contributing to the market growth[5].

Q4: What are the main distribution channels for medical nitroglycerin sprays? Conventional retail pharmacies and online pharmacies are the main distribution channels, with online pharmacies gaining increasing market share[5].

Q5: What are some of the challenges faced by the medical nitroglycerin sprays market? Challenges include prolonged migraines associated with frequent use, stringent regulatory requirements, and data security and privacy concerns[2][3].

Cited Sources

1. vTv Therapeutics Announces FDA Submission for First Phase 3 Study - vTv Therapeutics.
2. Medical Nitroglycerin Sprays Market Share & Forecast to 2033 - Future Market Insights.
3. Global Clinical Trials Market – Industry Trends and Forecast to 2030 - Data Bridge Market Research.
4. NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial - Stock Titan.
5. Medical Nitroglycerin Sprays Market Size, Share, Growth, Analysis - Zion Market Research.